GlassScriptPhysician profile
Susan B Munn
NPI 1538112404
$10,354.67
in general payments reported to CMS, 2019-2025
51 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $1,256 · 2021: $1,502 · 2022: $1,391 · 2023: $1,594 · 2024: $1,683 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,907 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,907.24 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,312.28 | 2020-2025 | |
| Novo Nordisk INC | $1,212.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $832.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $748.01 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $691.58 | 2019-2025 | |
| Lilly USA, LLC | $675.86 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.78 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $454.03 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $434.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Insulet Corporation | $352.20 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $304.39 | 2019-2025 | Capvaxive, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $265.39 | 2019-2023 | |
| Abbott Laboratories | $259.91 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.97 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $185.42 | 2023-2025 | Veozah |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Munn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.